NDC 0135-0200

ABREVA

Docosanol

ABREVA is a Topical Cream in the Human Otc Drug category. It is labeled and distributed by Glaxosmithkline Consumer Healthcare Holdings (us) Llc. The primary component is Docosanol.

Product ID0135-0200_2f3cffc6-42f0-4ba8-9ee7-2608e02f0b7b
NDC0135-0200
Product TypeHuman Otc Drug
Proprietary NameABREVA
Generic NameDocosanol
Dosage FormCream
Route of AdministrationTOPICAL
Marketing Start Date2010-03-19
Marketing CategoryNDA / NDA
Application NumberNDA020941
Labeler NameGlaxoSmithKline Consumer Healthcare Holdings (US) LLC
Substance NameDOCOSANOL
Active Ingredient Strength100 mg/g
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 0135-0200-01

2 g in 1 TUBE (0135-0200-01)
Marketing Start Date2010-03-19
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0135-0200-03 [00135020003]

ABREVA CREAM
Marketing CategoryNDA
Application NumberNDA020941
Product TypeHUMAN OTC DRUG
Billing UnitGM
Marketing Start Date2010-03-19
Inactivation Date2020-01-31

NDC 0135-0200-01 [00135020001]

ABREVA CREAM
Marketing CategoryNDA
Application NumberNDA020941
Product TypeHUMAN OTC DRUG
Billing UnitGM
Marketing Start Date2010-03-19
Inactivation Date2020-01-31

NDC 0135-0200-04 [00135020004]

ABREVA CREAM
Marketing CategoryNDA
Application NumberNDA020941
Product TypeHUMAN OTC DRUG
Marketing Start Date2010-03-19
Inactivation Date2020-01-31

NDC 0135-0200-05 [00135020005]

ABREVA CREAM
Marketing CategoryNDA
Application NumberNDA020941
Product TypeHUMAN OTC DRUG
Billing UnitGM
Marketing Start Date2017-07-06
Inactivation Date2020-01-31

Drug Details

Active Ingredients

IngredientStrength
DOCOSANOL100 mg/g

OpenFDA Data

SPL SET ID:c39b38a7-dcdd-4c32-8f35-b565c4d3cec6
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 855205
  • 797534

    • NDC Crossover Matching brand name "ABREVA" or generic name "Docosanol"

    NDCBrand NameGeneric Name
    0135-0200ABREVAdocosanol
    0135-0300ABREVAdocosanol
    50090-3476ABREVAABREVA
    30142-322Cold Sore Fever BlisterDocosanol
    0363-9220Cold Sore Fever Blister TreatmentDocosanol
    0363-9222Cold Sore Fever Blister TreatmentDocosanol
    11673-846Cold Sore Fever Blister TreatmentDocosanol
    11673-926Cold Sore Fever Blister TreatmentDocosanol
    11822-0951Cold Sore Fever Blister TreatmentDocosanol
    11822-3927Cold Sore Fever Blister TreatmentDocosanol
    11822-3951Cold Sore Fever Blister TreatmentDocosanol
    11822-3977Cold Sore Fever Blister TreatmentDocosanol
    11822-4763Cold Sore Fever Blister TreatmentDocosanol
    21130-823Cold Sore Fever Blister TreatmentDocosanol
    30142-981Cold Sore Fever Blister TreatmentDocosanol
    0363-2981DocosanolDocosanol
    0472-2981DocosanolDocosanol
    0591-2981DocosanolDocosanol
    21130-422DocosanolDocosanol
    21922-023DocosanolDocosanol

    Trademark Results [ABREVA]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    ABREVA
    ABREVA
    86790357 4932565 Live/Registered
    GlaxoSmithKline Consumer Healthcare (UK) IP Limited
    2015-10-16
    ABREVA
    ABREVA
    86790349 not registered Dead/Abandoned
    GlaxoSmithKline Consumer Healthcare (UK) IP Limited
    2015-10-16
    ABREVA
    ABREVA
    85708911 4317131 Live/Registered
    SmithKline Beecham (Cork) Limited
    2012-08-21
    ABREVA
    ABREVA
    85582078 not registered Dead/Abandoned
    SmithKline Beecham (Cork) Limited
    2012-03-28
    ABREVA
    ABREVA
    78023883 2550142 Dead/Cancelled
    SMITHKLINE BEECHAM (CORK) LIMITED
    2000-08-31
    ABREVA
    ABREVA
    78023878 2492774 Dead/Cancelled
    SMITHKLINE BEECHAM (CORK) LIMITED
    2000-08-31
    ABREVA
    ABREVA
    78023873 2502156 Dead/Cancelled
    SMITHKLINE BEECHAM (CORK) LIMITED
    2000-08-31
    ABREVA
    ABREVA
    77426076 not registered Dead/Abandoned
    SMITHKLINE BEECHAM (CORK) LIMITED
    2008-03-19
    ABREVA
    ABREVA
    75571530 2464248 Live/Registered
    GLAXOSMITHKLINE CONSUMER HEALTHCARE (UK) IP LIMITED
    1998-10-16
    © 2025 FDA.report
    This site is not affiliated with or endorsed by the FDA.